Director/Senior Director
Lexeo Therapeutics
Director/Senior Director
Lexeo Therapeutics
Gene therapy for cardiac, neurological diseases
Salary Range: 247500 to 382000 (Currency: USD) (Pay period: per-year-salary)
Role Summary
Lexeo is seeking an experienced and motivated clinical development leader to advance late-stage development programs as a key member of our development team. This individual will report to the Vice President, Clinical Development, Cardiology and will provide strategic and hands-on leadership across clinical strategy, study execution, and cross-functional integration to deliver high-quality evidence to support regulatory interactions and submissions (e.g., BLA). This role requires strong scientific and operational judgment and the ability to build effective partnerships with internal stakeholders and external collaborators.
About Lexeo
Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.
Our work culture is a hybrid model with 2 days/week in the New York City office and 3 days working from home.
Lexeo Therapeutics is an EEO employer committed to an exciting, diverse, and enriching work environment.
Gene therapy for cardiac, neurological diseases
Lexeo Therapeutics develops gene therapies for genetic cardiac and neurological diseases. It advances therapies by conducting research, running clinical trials, and pursuing commercialization through partnerships and grants. It differentiates itself with a strong academic foundation and collaboration with Weill Cornell’s Department of Genetic Medicine, while focusing on end-to-end development from discovery to trials. Its goal is to bring genetic medicines to patients with unmet medical needs through partnerships, clinical trials, and eventual market availability.
Explore more opportunities at Lexeo Therapeutics